Update shared on10 Aug 2025
Fair value Decreased 5.07%Despite a notable improvement in both future P/E and net profit margin, Intellia Therapeutics’ consensus analyst price target has been revised downward from $37.11 to $35.23.
What's in the News
- Phase 3 HAELO trial for lonvo-z in hereditary angioedema (HAE) is ongoing, showing strong interim efficacy data; drug has received multiple regulatory designations, including FDA Orphan Drug and RMAT.
- Enrollment in global Phase 3 HAELO study of NTLA-2002 for HAE is on track, with completion expected in Q3 2025 and a potential BLA submission in H2 2026 for a 2027 U.S. launch.
- Phase 3 MAGNITUDE-2 study of nex-z for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) is progressing well, with over 200 patients dosed and adverse events consistent with earlier studies.
- Two-year follow-up data from ongoing Phase 1 trial of nex-z for ATTRv-PN show deep, durable, and consistent TTR reductions; Phase 3 MAGNITUDE-2 trial is evaluating efficacy and safety, aiming for BLA submission by 2028.
Valuation Changes
Summary of Valuation Changes for Intellia Therapeutics
- The Consensus Analyst Price Target has fallen from $37.11 to $35.23.
- The Future P/E for Intellia Therapeutics has significantly fallen from 101.04x to 56.29x.
- The Net Profit Margin for Intellia Therapeutics has significantly risen from 10.54% to 13.95%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.